ScoreWhy is Regeneron Pharmaceuticals, Inc. ?
1
High Management Efficiency with a high ROE of 23.74%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 12.19% and Operating profit at 7.38%
4
Flat results in Jun 25
- ROCE(HY) Lowest at 15.34%
- DEBT-EQUITY RATIO (HY) Highest at -15.98 %
5
With ROE of 14.39%, it has a very attractive valuation with a 2.29 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 5.04%, its profits have fallen by -1.4%
6
High Institutional Holdings at 89.14%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Regeneron Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Regeneron Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Regeneron Pharmaceuticals, Inc.
-3.57%
-0.52
41.45%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.19%
EBIT Growth (5y)
7.38%
EBIT to Interest (avg)
87.72
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.46
Tax Ratio
9.73%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
89.14%
ROCE (avg)
33.12%
ROE (avg)
23.74%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.29
EV to EBIT
15.35
EV to EBITDA
13.64
EV to Capital Employed
2.64
EV to Sales
4.32
PEG Ratio
NA
Dividend Yield
0.28%
ROCE (Latest)
17.20%
ROE (Latest)
14.39%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 4,743.5 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
DIVIDEND PAYOUT RATIO(Y)
Highest at 6.87%
RAW MATERIAL COST(Y)
Fallen by 1.41% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 2.51 times
DIVIDEND PER SHARE(HY)
Highest at USD 2.51
EPS(Q)
Highest at USD 12.81
-3What is not working for the Company
ROCE(HY)
Lowest at 15.34%
DEBT-EQUITY RATIO
(HY)
Highest at -15.98 %
Here's what is working for Regeneron Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 4,743.5 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
EPS
Highest at USD 12.81
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 2.51 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Dividend per share
Highest at USD 2.51
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (USD)
Dividend Payout Ratio
Highest at 6.87%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Raw Material Cost
Fallen by 1.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 135.1 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Regeneron Pharmaceuticals, Inc.
Debt-Equity Ratio
Highest at -15.98 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
